{"id":55284,"date":"2023-03-29T00:03:32","date_gmt":"2023-03-28T22:03:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/"},"modified":"2023-03-29T00:03:32","modified_gmt":"2023-03-28T22:03:32","slug":"kontrol-technologies-to-report-fiscal-year-end-2022-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/","title":{"rendered":"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results"},"content":{"rendered":"
\n

TORONTO–(BUSINESS WIRE)–Kontrol Technologies Corp. <\/b>(NEO:KNR<\/a>) (OTCQB:KNRLF<\/a>) (FSE:1K8<\/a>) (“Kontrol Technologies<\/b>” or \u201cKontrol<\/b>\u201d or “Company<\/b>“) a leader in smart buildings and cities through IoT, Cloud and SaaS technology will report its Fiscal Year End 2022 financial results, for the period ended December 31st<\/sup>, 2022, on March 31st<\/sup>, 2023 (the \u201cfiling date\u201d). A complete set of the Financial Statements and Management’s Discussion & Analysis will also be filed on SEDAR (www.sedar.com<\/a>) on the filing date.\n<\/p>\n

<\/a><\/p>\n

\nA call and presentation to discuss the financial results has been scheduled for Friday, March 31st<\/sup>, 2023, at 4:30 PM (Eastern). The event will be hosted by Paul Ghezzi, CEO and Claudio Del Vasto, CFO, of Kontrol Technologies Corp. Included in the presentation is a Q and A session with management. We kindly request all participants to please connect at least 5 minutes prior to the event start time.\n<\/p>\n

\nEvent Details:<\/b>\n<\/p>\n\n\n\n\n\n\n
\n

\nTitle<\/b>\n<\/p>\n<\/td>\n

\n

\nKontrol Technologies Reports Fiscal Year End 2022 Financial Results\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEvent Date and Time<\/b>\n<\/p>\n<\/td>\n

\n

\nMarch 31st<\/sup>, 2023 @ 4:30 PM Eastern\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEvent Duration<\/b>\n<\/p>\n<\/td>\n

\n

\n45 Minutes\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRapid Connect URL<\/b>\n<\/p>\n<\/td>\n

\n

\nhttps:\/\/emportal.ink\/40dSJzH<\/a>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCall- in Numbers<\/b>\n<\/p>\n<\/td>\n

\n

\nLocal: 416-764-8609 (Toronto)\n<\/p>\n

\nNorth American Toll Free: 888-390-0605\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nConference Replay:<\/b>\n<\/p>\n\n\n\n\n\n
\n

\nConference Replay Local<\/b>\n<\/p>\n<\/td>\n

\n

\n416-764-8677\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nConference Replay Toll Free<\/b>\n<\/p>\n<\/td>\n

\n

\n1-888-390-0541\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nConference Replay Entry Code<\/b>\n<\/p>\n<\/td>\n

\n

\n651919 #\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nConference Replay Expiration Date<\/b>\n<\/p>\n<\/td>\n

\n

\nApril 7th<\/sup>, 2023\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nKontrol Technologies Corp.<\/b>\n<\/p>\n

\nKontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides solutions and services to its customers to improve energy management, monitor continuous emissions and accelerate the sustainability of all buildings.\n<\/p>\n

\nAdditional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com<\/a> and by reviewing its profile on SEDAR at www.sedar.com<\/a>\n<\/p>\n

\nNeither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.<\/b>\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis news release contains \u201cforward-looking information\u201d within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as \u201cmay\u201d, \u201cwill\u201d, \u201cexpect\u201d, \u201clikely\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201cplan\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cpotential\u201d, \u201cproposed\u201d, \u201cestimate\u201d, \u201cbelieve\u201d or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions \u201cmay\u201d or \u201cwill\u201d happen, or by discussions of strategy.<\/i>\n<\/p>\n

\nWhere Kontrol expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.<\/i>\n<\/p>\n

\nHowever, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all; that those technologies will not prove as effective as expected; those customers and potential customers will not be as accepting of the Company’s product and service offering as expected; and government and regulatory factors impacting the energy conservation industry.<\/i>\n<\/p>\n

\nAccordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKontrol Technologies Corp.
\n
<\/b>Paul Ghezzi, CEO
\n
info@kontrolcorp.com<\/a>
11 Cidermill Avenue, Suite 201
\n
Vaughan, ON L4K 4B6
\n
Tel: (905) 766.0400\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TORONTO–(BUSINESS WIRE)–Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or \u201cKontrol\u201d or “Company“) a leader in smart buildings and cities through IoT, Cloud and SaaS technology will report its Fiscal Year End 2022 financial results, for the period ended December 31st, 2022, on March 31st, 2023 (the \u201cfiling date\u201d). A complete set of the Financial … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55284","6":"format-standard","7":"category-industry"},"yoast_head":"\nKontrol Technologies to Report Fiscal Year End 2022 Financial Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORONTO–(BUSINESS WIRE)–Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or \u201cKontrol\u201d or “Company“) a leader in smart buildings and cities through IoT, Cloud and SaaS technology will report its Fiscal Year End 2022 financial results, for the period ended December 31st, 2022, on March 31st, 2023 (the \u201cfiling date\u201d). A complete set of the Financial ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T22:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230328005897\/en\/1231614\/21\/Kontrol_Technologies_Corp.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results\",\"datePublished\":\"2023-03-28T22:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/\"},\"wordCount\":703,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005897\\\/en\\\/1231614\\\/21\\\/Kontrol_Technologies_Corp.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/\",\"name\":\"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005897\\\/en\\\/1231614\\\/21\\\/Kontrol_Technologies_Corp.jpg\",\"datePublished\":\"2023-03-28T22:03:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005897\\\/en\\\/1231614\\\/21\\\/Kontrol_Technologies_Corp.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005897\\\/en\\\/1231614\\\/21\\\/Kontrol_Technologies_Corp.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results - Pharma Trend","og_description":"TORONTO–(BUSINESS WIRE)–Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or \u201cKontrol\u201d or “Company“) a leader in smart buildings and cities through IoT, Cloud and SaaS technology will report its Fiscal Year End 2022 financial results, for the period ended December 31st, 2022, on March 31st, 2023 (the \u201cfiling date\u201d). A complete set of the Financial ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-28T22:03:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230328005897\/en\/1231614\/21\/Kontrol_Technologies_Corp.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results","datePublished":"2023-03-28T22:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/"},"wordCount":703,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005897\/en\/1231614\/21\/Kontrol_Technologies_Corp.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/","url":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/","name":"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005897\/en\/1231614\/21\/Kontrol_Technologies_Corp.jpg","datePublished":"2023-03-28T22:03:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230328005897\/en\/1231614\/21\/Kontrol_Technologies_Corp.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230328005897\/en\/1231614\/21\/Kontrol_Technologies_Corp.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kontrol-technologies-to-report-fiscal-year-end-2022-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kontrol Technologies to Report Fiscal Year End 2022 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55284"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55284\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}